The estimated Net Worth of Robert Janssen is at least $3.76 Million dollars as of 10 February 2024. Dr Janssen owns over 4,333 units of Dynavax Technologies stock worth over $656,946 and over the last 11 years he sold DVAX stock worth over $2,378,540. In addition, he makes $725,275 as Chief Medical Officer and Sr. VP of Clinical Devel. and Medical & Regulatory Affairs at Dynavax Technologies.
Dr has made over 31 trades of the Dynavax Technologies stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 4,333 units of DVAX stock worth $47,273 on 10 February 2024.
The largest trade he's ever made was exercising 89,405 units of Dynavax Technologies stock on 16 November 2021 worth over $936,070. On average, Dr trades about 11,637 units every 61 days since 2013. As of 10 February 2024 he still owns at least 60,215 units of Dynavax Technologies stock.
You can see the complete history of Dr Janssen stock trades at the bottom of the page.
Dr. Robert Janssen is the Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs at Dynavax Technologies.
As the Chief Medical Officer and Sr. VP of Clinical Devel. and Medical & Regulatory Affairs of Dynavax Technologies, the total compensation of Dr Janssen at Dynavax Technologies is $725,275. There are 2 executives at Dynavax Technologies getting paid more, with Ryan Spencer having the highest compensation of $859,990.
Dr Janssen is 67, he's been the Chief Medical Officer and Sr. VP of Clinical Devel. and Medical & Regulatory Affairs of Dynavax Technologies since . There are 1 older and 4 younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.
Robert's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog..., and James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: